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Background. Despite a number of in vitro and in vivo studies reporting the efficacy of fucoidan in treating various cancers, few studies
have measured the efficacy of dietary fucoidan (DF) in combination with cancer drugs. Thus, we examined the sensitivity of DF in
combination with the EGFR/ERBB2-targeting reagent lapatinib on cancer cells. Method. We selected six EGFR/ERBB2-amplified
cancer cell lines (OE19, NCI-N87, OE33, ESO26, MKN7, and BT474) as an in vitro model and tested their sensitivity to DF alone
and to DF in combination with the well-known EGFR/ERBB2-targeting reagent lapatinib. Result. Overall, in drug independent
sensitivity test, DF alone did not significantly inhibit the growth of EGFR/ERBB2-amplified cancer cells in vitro. When DF was
given in combination with lapatinib, however, it tended to synergistically inhibit cell growth in OE33 but antagonized the action
of lapatinib in ESO26, NCI-N87, and OE19. Conclusion. This study suggests that DF has the potential to increase or decrease the
effects of certain anticancer drugs on certain cancer cell types. Further study is needed to explore the mechanism of interaction and
synergistic antitumor activity of DF in combination with chemotherapy and targeted therapy.
1. Introduction
The use of dietary supplements (DS) is gaining in global pop-
ularity as a form of complementary and alternative medicine
(CAM) [1, 2]. DS, defined as any product that contains vit-
amins, minerals, herbs or other botanicals, amino acids, enz-
ymes, and/or other ingredients intended to supplement diet,
is currently one of the most increasingly used CAM therapies
[3]. A study found that 69% of the cancer patients in the US
use DS following their cancer diagnosis [4]. A recent Aus-
tralian survey with cancer patients also reported that approx-
imately 69% of respondents had used one form of CAM in
the previous year and 41% of them had visited a CAM practi-
tioner [5]. Currently, thousands of DS products are available
over the counter without health professionals’ prescription,
though the majority of DS have yet to be evaluated in clinical
trials. Thus, most oncologists are concerned about possible
herb-drug interactions that might occur with conventional
anticancer drugs resulting in either excess toxicity or reduced
efficacy [6]. A few studies have examined the interaction
between herbs and chemotherapy drugs, but none have been
examined yet to look at targeted agents [6]. And so, study on
DS is essential to provide evidence-based information for
cancer patients as well as healthcare practitioners.
Fucoidan, one kind of DS, has been reported to exhibit
anti-inflammatory, antibacterial, antiviral, immunomodulat-
ing, antiangiogenesis, and antitumor activities [7–10]. Fuc-
oidan, a sulfated polysaccharide found in cell walls of various
species of brown and green seaweeds, is known to contain lar-
ge proportions of L-fucose and sulfate along with low amo-
unts of xylose, uronic acid, and galactose [9, 11]. Seaweed and
marine algae have been used as food and medicine for over
a thousand years in Asia and in some parts of northern
Europe [12]. Recently, the antitumor effect of fucoidan has
been studied intensively. Studies have reported that the intake
of seaweed is associated with a lower incidence of breast
cancer [13, 14].
A recent study of patients with unresectable advanced or
recurrent colorectal cancer suggests that fucoidan has the
potential to reduce the toxicities of chemotherapy [15]. In
vivo studies conducted using mouse xenograft models have
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suggested that fucoidan suppresses the growth of 4T1-derived
breast cancer [16], A20-derived lymphoma [17], and Ehrlich
ascites carcinoma [18], inhibits metastasis of Lewis lung
adenocarcinoma [19] and 13762 MAT rat mammary ade-
nocarcinoma, [20] and has antiangiogenesis activity against
B16 melanoma [21]. The lines of evidence of in vitro studies
have demonstrated that fucoidan inhibits the growth of non-
small cell bronchopulmonary carcinoma NSCLCN6 cells
[22] and human lymphoma HS-Sultan cells [23] and also
induces apoptosis in cells derived from human lymphoma
[23], promyelocytic leukemia [24], colon carcinoma [7],
breast carcinoma [16], ovarian carcinoma, and hepatoma
[25], including the prevention of angiogenesis by suppressing
expression and secretion of the angiogenesis factor, vascu-
lar endothelial growth factor (VEGF) [26]. However, the
mechanism involved in the anticancer action of fucoidan is
incompletely understood, and further studies on fucoidan
and chemotherapy interactions are limited.
Lapatinib, a targeted therapy that acts as a tyrosine kinase
inhibitor, is extensively used to treat advancedHER2-positive
breast cancer as well as other cancers [27]. Tyrosine kinases
are plasma membrane proteins that signal cells to divide and
grow. Lapatinib blocks signals from these proteins which
help to slow cancer cell growth [27]. In particular, lapatinib
interferes with protein tyrosine kinases, epidermal growth
factor receptor type 1 (EGFR (ERBB1)), and human epidermal
receptor type 2 (HER (ERBB2)). Lapatinib, administered
orally as active small molecules, interferes with the growth of
cancer cells and potentially with the growth of normal cells.
Cancer patients receiving targeted therapy lapatinib may
have used fucoidan as a DS, although drug interactions of
fucoidan-anticancer targeted therapy have not been studied.
Hence, in our current study, we examined the sensitivity of
OE19, OE33, ESO26, NCI-N87, BT474, and MKN7 cancer
cells to DF and to DF in combination with lapatinib.
2. Material and Method
2.1. Cell Lines and Reagents. OE19, NCI-N87, OE33, and
ESO26 cells were obtained from the American Type Culture
Collection (ATCC) and MKN7 cells were obtained from the
Japanese Cell Resource Bank (JCRB). BT474 cells were kindly
provided by the Hahn Laboratory. Lapatinib was purchased
fromLCLaboratories andwas dissolved in dimethylsulfoxide
(DMSO) (Sigma-Aldrich, St. Louis, MO). Samples of dietary
fucoidan extract were obtained from EnzAlg Bio Sciences
(New Zealand) and were dissolved in phosphate-buffered
saline (PBS).
2.2. Cell Culture. All cell lines were maintained by RPMI-
1640 medium (Mediatech, Manassas, VA) supplemented
with 10% Fetal Bovine Serum (Gemini Bio-Products, West
Sacramento, CA) and were kept in a humidified incubator at
5% CO2. For all cell lines, the passage number was carefully
controlled and mycoplasma contamination was monitored
on a regular basis.
2.3. Drug Sensitivity Assay. For a drug sensitivity assay,
we used Cell-Titer Glo cell viability luminescence assay
(Promega). Briefly, cells were plated at a desired density
(OE19, 2 × 103; OE33 and MKN7, 1 × 103; NCI-N87, 3 ×
10
3; ESO26 and BT474, 5 × 103) in 96-well plates. After 24
hours, cells were treated with variable doses of lapatinib or
fucoidan extract alone or in combination and then cultured
for 72 hours. In the control, cells were treated with DMSO
for lapatinib and PBS for fucoidan extract. At the end of
the experiment, the number of viable cells was estimated
using the Cell-Titer Glo luminescence assay according to the
manufacturer’s instructions. All experiments were repeated
three times with each biological replicate including [4]
replicates per treatment condition.
2.4. Statistical Method. A dose-inhibition curve was drawn
from the results of the drug sensitivity assay by calculat-
ing percent inhibition (100 × cell growth rates of drug-
treated wells/growth rates of vehicle-treated wells) and log-
transforming the drug doses. IC
50
values were estimated
based on the curves obtained. In the herb-drug combination
experiments, the statistical significances of the differences in
cell growthwere estimated by one-wayANOVA.All statistical
analyses were done using GraphPad Prism software (Ver
6.0a).
3. Results
3.1. Various ERBB2-Amplified Gastroesophageal and Breast
Cancer Cell Lines Show Different Sensitivities to Lapatinib.
ERBB2 amplification has been known to predict the sensi-
tivity to the EGFR/ERBB2-targeted small molecule inhibitor,
lapatinib [27]. However, the in vitro drug sensitivity assay
performed in this study revealed variable drug sensitivity pro-
files among the different ERBB2-amplified cell lines (details
regarding differential sensitivity of cell lines to lapatinib
are being reported separately (manuscript in preparation)).
OE19, NCI-N87, and BT474 cells were sensitive to lapatinib
whereas OE33 and MKN7 cells were resistant to lapatinib.
ESO26 cells were moderately sensitive to lapatinib (Figure 1).
IC
50
values are summarized in Table 1.
3.2. Fucoidan Extract Does Not Have Significant In Vitro
Growth Inhibitory Effect on Various ERBB2-Amplified Gas-
troesophageal and Breast Cancer Cell Lines. Overall, in dose-
dependent drug sensitivity test, DF, as a single agent, did not
significantly inhibit the growth of EGFR/ERBB2-amplified
gastroesophageal and breast cancer cell lines even at supra-
pharmacological doses (Figure 2). Only OE33 and ESO26
cells showed equivocal trends of dose-dependent growth
inhibition.
3.3. Fucoidan Extract, When Combined with Lapatinib, Has
Variable Effects on Cancer Cell Growth in Different Cell Lines.
Treatment with 20𝜇g/mL of DF has a less significant effect on
inhibition of OE33 cell growth than that of 1 𝜇M of lapatinib.
When DF was combined with lapatinib, it tended to be
more effective on the inhibition of OE33 cell than lapatinib
alone, but the difference was not significant (Figure 3(a)).
However, DF treatment with 20𝜇g/mL increased the growth
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Table 1: IC50 values of the various ERBB2-amplified gastroe-
sophageal and breast cancer cells treated with lapatinib.
Cell lines IC50 (nM)
OE19 188
NCI-N87 34
BT474 236
ESO26 433
OE33 >1,000
MKN7 >1,000
of OE19 cells as well as DF in combination with lapatinib
(Figure 3(b)). In ESO26 and NCI-N87 cells, DF had antago-
nistic effects on cell growth when combined with lapatinib,
while DF alone had no significant effect (Figures 3(c) and
3(d)). In MKN7 and BT474 cells, DF had no effect on cell
growth either as a single agent or in combination with
lapatinib (Figures 3(e) and 3(f)).
4. Discussion
Dietary supplementation is most commonly used by cancer
patients even though there is limited evidence on its efficacy
in this patient population. In the last decade, numerous
in vivo and in vitro studies have suggested that fucoidan,
extracted from seaweed, has an anticancer effect. No pub-
lished randomized controlled trial (RCT) has assessed the
effect of fucoidan when combined with targeted therapy
pharmacokinetics, despite the fact that no adverse reactions
had been reported from the use of fucoidan [28]. Thus, to
investigate a fucoidan-drug interaction prior to a design of
a future clinical trial, we examined the sensitivity of DF alone
and in combination of lapatinib (kinase inhibitor) on OE19,
OE33, ESO26, NCI-N87, BT474, andMKN7 cancer cells. Our
study found that DF extract alone had no significant growth
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inhibitory effect on various EGFR/ERBB2-amplified gastroe-
sophageal and breast cancer cell lines in vitro. However, it
did exhibit a synergistic effect on OE33 when combined with
lapatinib, while exhibiting an antagonistic effect onNCI-N87,
ESO26, and OE19 cancer cells. These results suggest that the
effect of DF plus lapatinib may be cell type dependent.
Recently, two studies have reported the effect of fucoidan
on cancer when administered in combination with cancer
drugs. Zhang et al. examined the effect of fucoidan plus
chemotherapy agents (cisplatin, tamoxifen, or paclitaxel) on
breast cancer cells (MDA-MB-231 and MCF-7). The results
demonstrated that fucoidan in combination with cisplatin,
tamoxifen, or paclitaxel significantly enhanced cell death of
MDA-MB-231 and MCF-7 breast cancer cells by regulating
the expression of Bcl-2 family proteins, modulating ERK
and Akt signaling, and regulating the production of oxida-
tive stress [29]. Our current study suggests that fucoidan
plus the targeted cancer drug lapatinib can have either an
synergistic or antagonistic effect, depending on the type of
cancer cell treated. Although we did not experiment on the
same cancer cell types as those used in the Zhang et al.
study, our results are inconsistent with the findings in the
Zhang et al. study. In the second recent study, Ikeguchi
et al. conducted a clinical trial on unresectable advanced or
recurrent colorectal cancer patients (𝑛 = 20) to investigate the
effect of fucoidan in combination with chemotherapy (oxali-
platin plus 5-fluorouracil/leucovorin (FOLFOX) or irinote-
can plus 5-fluorouracil/leucovorin (FOLFIRI)) and reported
that fucoidan plus FOLFOX or FOLFIRI has the potential to
reduce the toxicity and improve survival by prolonging the
duration of clinical effectiveness of chemotherapy [15]. As
a result, the need for further studies on the application of
fucoidan in combination with chemo- and/or targeted drug
approaches was suggested to address management of toxicity,
clinical outcome, and mechanism of herb-drug interaction.
A major limitation of this study is that experiments were
performed in vitro. However, to our knowledge, this is the
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first study that has examined and demonstrated a potential
DF-targeted therapy lapatinib interaction. Clinical trials and
animal testing are needed to confirm the results of our
study as the next step towards clinical application. Another
limitation is that the quality of DF product (e.g., structure,
composition, or molecular weight) was not evaluated. The
study was designed to examine the anti-cancer effects on
cancer cells with DF available to cancer patients as a com-
mercial over-the-counter product available without doctor’s
prescription.
Recent literature reviews have suggested that amajor con-
cern among doctors is the use of CAMbefore and during can-
cer treatment due to potential herb-drug interactions reduc-
ing the efficacy of cancer treatment or producing adverse
effects. Azuma et al. suggested that, regardless of molecu-
lar weight (lower-molecular-weight fucoidan (LMWF: 6.6–
40 kDa), intermediate-molecular-weight fucoidan (IMWF:
110–138 kDa), and high-molecular-weight fucoidan (HMWF:
300–330 kDa)), fucoidan-containing diet increases the sur-
vival time of mice [30]. Still, Matsubara et al. argue that
the pharmacological effects of fucoidan vary with molecular
weight [31]. Hence, further studies are required to determine
if molecular weight of fucoidan is associated with the inhi-
bition of tumor growth and an increase in the efficacy of
targeted drugs. It will also be beneficial to test the efficacy
of DF in combination with multiple cancer drugs on various
cancer cells to establish herb-drug interaction guidelines and
to discover potential new drugs that can enhance survival
of cancer patients. Furthermore, our present study did not
examine the mechanism of fucoidan-lapatinib interaction.
Further in vivo and clinical studies are required to address
a potential fucoidan-drug interaction.
In conclusion, co-administration of DF and lapatinib in
cancer patients produces a potential herb-drug interaction.
An animal study and clinical trial are necessary to evaluate
the pharmacodynamic impact of fucoidan on molecularly
targeted therapy and chemotherapy in cancer treatment.
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